Emine Yıldırım

Dr. Emine Yıldırım

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Academic Radiology
Verified
Journal Article
Closed access
YKyasemin kayadibi
yasemin kayadibi
BKBurak Kocak
Burak Kocak
NUNese Ucar
Nese Ucar
YAYesim Namdar Akan
Yesim Namdar Akan
EYEmine Yıldırım
Emine Yıldırım
SBSibel Bektaş
Sibel Bektaş

Verified
Journal Article
Open access
PDF file
ASadem senturk
adem senturk
NKNur Kazan
Nur Kazan
SSSELEN SEN
SELEN SEN
GÇGözde Çakırsoy Çakar
Gözde Çakırsoy Çakar
LALaçin tatlı ayhan
Laçin tatlı ayhan
HUHafize Uzun
Hafize Uzun
Breast cancer (BC) is a heterogeneous disease with distinct molecular subtypes that exhibit variable immune responses and metabolic profiles. Recent studies have suggested that immunometabolic pathways play a role in tumor progression and treatment resistance. This study investigates the expression patterns of ALKBH7 and NLRP3 across BC molecular subtypes and explores their relationships with clinicopathological parameters and potential immunometabolic profiles. A total of 118 BC patients were classified into HER2+, TNBC, Luminal A, and Luminal B subtypes. Gene expression levels of ALKBH7 and NLRP3 were analyzed using quantitative real-time PCR (qRT-PCR), and correlations with clinical markers were assessed. ALKBH7 and NLRP3 expression levels varied significantly between subtypes, with the highest expression observed in HER2+ tumors. Strong positive correlations were found between ALKBH7 and NLRP3 in all subtypes, particularly in HER2+ (r = 0.812, p < 0.001). Additionally, NLRP3 correlated with Ki-67 in Luminal B tumors, indicating a link between inflammation and proliferative capacity. These findings suggest that ALKBH7 may function as a dual-role biomarker involved in metabolic adaptation and immune signaling in BC. The strong co-expression of ALKBH7 and NLRP3 suggests a functional association between these molecules that may be critical in shaping the tumor microenvironment. This co-expression set, particularly in aggressive subtypes (HER2+ and TNBC), warrants further mechanistic validation as a potential prognostic marker and a novel therapeutic vulnerability.

28 September 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
EYEmine Yıldırım
Emine Yıldırım
SBSibel Bektas
Sibel Bektas
OGOzgecan Gundogar
Ozgecan Gundogar
DFDeniz Findik
Deniz Findik
SASerap Alcicek
Serap Alcicek
MYMete Yildiz
Mete Yildiz
Background: In recent years, GATA-binding protein 3 (GATA3) has been indicated as a marker showing good prognosis in breast cancer. In luminal breast cancer, which has good a prognosis, it shows more significant elevation in small-sized and low-grade tumors. In contrast, Ki-67 is defined as a poor prognostic factor. The aim of this study was to emphasise the prognostic importance of GATA3 and the inverse relationship with Ki-67. Materials and Methods: In our study, 90 patients with invasive ductal breast cancer were immunohistochemically evaluated for Ki-67 and GATA3 expression. The relationship between GATA3 and Ki-67 expression was examined. In addition, the relationship between these two factors with estrogen, progesterone, human epidermal growth factor 2 receptor antibodies and other prognostic parameters such as disease-free survival and local recurrence was investigated. We accepted the level of ≥5% nüclear reaction as positive for GATA 3. A Ki-67 cut-off value of 20% was accepted as positive. Results: In GATA3 positive breast cancers, good prognostic parameters were seen including high estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, small tumor size and low histological grade as well as low Ki-67 expression. In breast cancers showing high Ki-67 expression, ER, PR, and GATA3 positivity were lower and there was higher human epidermal growth factor receptor 2 (HER2) positivity and high histological grade while the tumor size was larger. Conclusion: Our study has revealed that GATA3 has an inverse relationship with Ki-67, whereas it has a positive releationship with good prognostic factors.

3 February 2022 in Clinical Imaging
Verified
Journal Article
Closed access
YKYasemin Kayadibi
Yasemin Kayadibi
NUNese Ucar
Nese Ucar
YAYesim Namdar Akan
Yesim Namdar Akan
MKMehmet Fatih Kaya
Mehmet Fatih Kaya
EYEmine Yıldırım
Emine Yıldırım
GIGul ESEN ICTEN
Gul ESEN ICTEN

1 September 2021 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
EYEmine Yıldırım
Emine Yıldırım
SBSibel Bektaş
Sibel Bektaş
ZPZekeriya Pelen
Zekeriya Pelen
IYIrem Yanik
Irem Yanik
AEAhmet Muzaffer Er
Ahmet Muzaffer Er
PGPerihan Gumuskaya
Perihan Gumuskaya

Verified
Journal Article
Open access
PDF file
PGPerihan Gumuskaya
Perihan Gumuskaya
ÖAÖzgür Altun
Özgür Altun
EYEmine Yıldırım
Emine Yıldırım
NYNur Karakutuk Yuztas
Nur Karakutuk Yuztas
NONeslihan Ozsoy
Neslihan Ozsoy
TTTufan Tukek
Tufan Tukek
Background: Much research has demonstrated that there is a relation between depression and chronic diseases. Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases, and it is an expanding global health problem. This study aims to explore the relationship between glycemic control (GC), antidiabetic agents, and depression in T2DM, focusing on how depression affects treatment adherence and GC. Methods: This prospective study included 250 patients with T2DM. Demographic information and laboratory results were obtained from the patients as well as from the hospital’s laboratory system. Beck’s Depression Inventory (BDI) scores, GC indicator HbA1c levels, and antidiabetic agents used by the patients were compared. Results: Upon analyzing the findings, we found a statistically significant positive correlation between the severity of depression and HbA1c levels (p < 0.001). Additionally, no significant relationship was observed between depression and the use of oral antidiabetic medications, except for metformin. However, a significant association between depression and insulin use was found even in patients with good GC (p < 0.001), regardless of whether HbA1c was high. Conclusions: Regardless of the type of antidiabetic treatment, diabetic patients receiving intensive insulin therapy, whether they have good or poor GC, should be carefully evaluated for depressive symptoms. Appropriate psychiatric support should be provided to help achieve GC and enhance their quality of life. Our study is the first to emphasize the importance of close monitoring for diabetic patients using insulin, even those with good GC. Understanding these interactions may improve disease management, patient outcomes, and quality of life.